NEW YORK, March 24, 2017 -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Cemtrex, Inc. (“Cemtrex” or the “Company”) (NASDAQ:CETX) of the April 25, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.
The lawsuit has been filed in the U.S. District Court for the Eastern District of New York on behalf of all those who purchased Cemtrex securities between February 11, 2016, and February 22, 2017 (the “Class Period”). The case, Cullinan v. Cemtrex, Inc. et al, No. 2:17-cv-01067 was filed on February 24, 2017, and has been assigned to Judge Joan Marie Azrack.
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Source Capital was at risk of having its registrations terminated for wrongdoing; (2) Cemtrex was utilizing paid stock promoters to inflate its stock price; (3) that Aron Govil, a director of the Company, was secretly paying stock promoters; (4) Company insiders engaged in insider selling; (5) the Company’s purported audit firm claimed to operate at a location that was vacant; (6) the controlling partner behind the Company’s auditor was banned by the Securities and Exchange Commission (“SEC”), among others, for conducting fraudulent audits or reviews; (7) the Company’s auditor was signing off on the Company’s financial disclosures without conducting a proper review; and (8) as a result, Cemtrex’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
Specifically, on February 17, 2017, the status of Source Capital’s FINRA and SEC registrations were listed as “Termination Requested.” On this news, Cemtrex’s share price fell from $5.77 on February 17, 2017 to a closing price of $5.12 on February 21, 2017—a $0.65 or a 11.27% drop.
Then, on February 22, 2017, an article was published on SeekingAlpha entitled “Cemtrex: Documents And Photos, All Signs Point To Deception And Failure.” On this news, Cemtrex’s share price fell from $5.12 on February 21, 2017 to a closing price of $3.40 on February 22, 2017—a $1.72 or a 33.59% drop.
Request more information now by clicking here: www.faruqilaw.com/CETX. There is no cost or obligation to you.
Take Action
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected].
Faruqi & Faruqi, LLP also encourages anyone with information regarding Cemtrex’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 685 Third Avenue, 26th Floor New York, NY 10017 Attn: Richard Gonnello, Esq. [email protected] Telephone: (877) 247-4292 or (212) 983-9330


Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 



